目的 探討復(fù)方嗜酸乳桿菌聯(lián)合曲美布汀治療腹瀉型腸易激綜合癥的臨床療效.方法 選擇上海市浦東新區(qū)光明中醫(yī)醫(yī)院2013 年6 月-2014 年6 月收治的120 例腹瀉型腸易激綜合征患者,隨機(jī)分為對(duì)照組(60 例)和治療組(60 例).對(duì)照組飯前30 min 口服給予馬來酸曲美布汀片0.1 g/次,3 次/d.治療組在對(duì)照組的基礎(chǔ)上飯后口服給予復(fù)方嗜酸乳桿菌片1 g/次,3 次/d.對(duì)照組和治療組患者均連續(xù)治療1 個(gè)月.觀察兩組患者的臨床療效,同時(shí)記錄腹痛積分、腹瀉積分、大便性狀異?；屎腿站疟愦螖?shù),檢測(cè)血清中的白細(xì)胞介素6(IL-6)、腫瘤壞死因子α(TNF-α)水平.結(jié)果 治療后,對(duì)照組和治療組的總有效率分別為80.0%、93.3%,,兩組總有效率比較差異有統(tǒng)計(jì)學(xué)意義(P< 0.05).治療后兩組的腹痛積分、腹瀉積分、大便性狀異?；屎腿站疟愦螖?shù)均較治療前顯著降低(P< 0.05);治療組治療后的腹痛積分、腹瀉積分、大便性狀異?；屎腿站疟愦螖?shù)均較對(duì)照組治療后顯著降低(P< 0.05).治療后兩組血清中的IL-6 和TNF-α 水平較治療前顯著降低(P< 0.05);治療后治療組血清中的IL-6 和TNF-α 水平較對(duì)照組顯著降低(P< 0.05).結(jié)論 復(fù)方嗜酸乳桿菌片聯(lián)合馬來酸曲美布汀片治療腹瀉型腸易激綜合征具有顯著的臨床療效,安全性較高,具有一定的臨床推廣價(jià)值.

Objective To explore the effect of Compound Eosinophil-Lactobacillus Tablets combined with trimebutine in treatment of diarrhea-predominant irritable bowel syndrome. Methods Patients (120 cases) with diarrhea-predominant irritable bowel syndrome in Pudong New Area Guangming Hospital of Traditional Chinese Medicine from June 2013 to June 2014 were randomly divided into control and treatment groups, and each group had 60 cases. The patients in the control group were po administered with Trimebutine Maleate Tablets 30 min before meals, 0.1 g/time, three times daily. The patients in the treatment group were po administered with Compound Eosinophil-Lactobacillus Tablets after meals on the basis of control group, 1 g/time, three times daily. The patients in the control and treatment groups were treated for 1 month. After treatment, the efficacy was evaluated, and abdominal pain score, diarrhea score, abnormal rate of stool characteristics, and defecating frequency were recorded. At the same time, the levels of IL-6 and TNF-α in serum were determined. Results The efficacies in the control and treatment groups were 80.0% and 93.3%, respectively, and there were differences between two groups (P < 0.05). After treatment, abdominal pain score, diarrhea score, the abnormal rate of stool characteristics, and defecating frequency in two groups were significantly decreased (P < 0.05), and these indicators in treatment group were lower than those in the control group (P < 0.05). After treatment, the levels of IL-6 and TNF-α in serum in two groups were obviously reduced (P < 0.05), and these indicators in treatment group were also lower than those in the control group (P < 0.05). Conclusions Compound Eosinophil-Lactobacillus Tablets combined with Trimebutine Maleate Tablets has significant clinical efficacy and good safety, which has a certain clinical application value.